Stephen Johnson

Stephen is a director, patent prosecution at Verve Therapeutics. Stephen has prosecuted patents in the USPTO and world-wide covering commercial pharmaceuticals, biologics, vaccines and pharmaceutical manufacturing processes for Wyeth, Pfizer, Novartis, Sun Pharma and the US Army. He has extensive experience with regulatory issues in the FDA and other regulatory health authorities that are associated with patent exclusivity of commercial medicines.

Prior to joining Verve, he headed patent prosecution for Johnson Matthey Health (Veranova) and DNA/RNA vaccine and biologics patents for the US Army Medical Research and Development Command at Ft. Detrick, including new adjuvant vaccine carriers (ALF-Q), Liposome Nanoparticle Formulations (LNFs), developed at WRAIR and USAMRIID. He was integral to developing and implementing the IP strategy for USAMRDC with regards to US government (USG) Pharma partnerships with Moderna, Pfizer and GSK on SARS2 CoV-19 vaccines.

Dr. Johnson graduated with a BS in chemistry, from Southern Illinois University and summa cum laude, with a Ph.D. in chemistry, from the University of Massachusetts, Amherst. He was awarded a National Science Foundation post-doctoral fellowship in chemistry at UCLA.